Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Eagle Pharmaceuticals (EGRX) Stock Price
Media stories about Eagle Pharmaceuticals (NASDAQ:EGRX) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 44.9403103353727 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Eagle Pharmaceuticals (EGRX) vs. Its Competitors Head-To-Head Comparison (americanbankingnews.com)
- Reviewing Eagle Pharmaceuticals (EGRX) & Aimmune Therapeutics (AIMT) (americanbankingnews.com)
- Tenet Healthcare Corp. (THC) is at $17.16 per share and Eagle Pharmaceuticals, Inc. (EGRX) is listed at $59.04 – Stocks Gallery (stocksgallery.com)
- Contrasting Eagle Pharmaceuticals (EGRX) and AbbVie (ABBV) (americanbankingnews.com)
- Reviewing Eagle Pharmaceuticals (EGRX) and The Competition (americanbankingnews.com)
Eagle Pharmaceuticals (EGRX) opened at 60.11 on Monday. The stock has a market cap of $911.81 million, a PE ratio of 10.09 and a beta of 1.30. The firm has a 50-day moving average price of $54.14 and a 200 day moving average price of $73.56. Eagle Pharmaceuticals has a 52-week low of $45.05 and a 52-week high of $97.15.
Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.51 by ($0.18). The company had revenue of $50.10 million for the quarter, compared to analyst estimates of $52.52 million. Eagle Pharmaceuticals had a net margin of 39.32% and a return on equity of 66.30%. The company’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.80 EPS. Equities analysts anticipate that Eagle Pharmaceuticals will post $3.70 earnings per share for the current year.
Eagle Pharmaceuticals announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, August 9th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the specialty pharmaceutical company to buy up to 13.3% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.
Several equities research analysts have recently commented on the company. Piper Jaffray Companies set a $118.00 price target on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Mizuho cut their price target on Eagle Pharmaceuticals from $40.00 to $37.00 and set an “underperform” rating for the company in a research note on Wednesday, September 6th. BidaskClub cut Eagle Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, July 31st. Royal Bank Of Canada set a $94.00 price target on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, July 16th. Finally, Zacks Investment Research cut Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 31st. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $74.80.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Eagle Pharmaceuticals (EGRX) Stock Price” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/18/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-eagle-pharmaceuticals-egrx-stock-price.html.
In other Eagle Pharmaceuticals news, Director Douglas L. Braunstein bought 20,400 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were purchased at an average price of $49.07 per share, with a total value of $1,001,028.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 19.50% of the stock is owned by insiders.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.